Brain is the ultimate frontier in health research. Depression, anxiety, dementia and similar conditions often are prodromes to more serious neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis etc. Inspired by the mechanisms of action of psychadelics, and the need for therapeutics to prevent, possibly reverse, neurodegeneration, Lucid is exploring novel therapies to address total brain health, i.e. mind and biology behind it!
Lucid is bringing together all possible tools to validate solutions at the bench to transition into clinical studies. Lucid scientists understand the value and the role of various tools such as artificial intelligence, chemical libraries, in vitro screening solutions, various animal models, pragmatic therapeutic strategies, regulatory approaches and clinical trials. With a bold thinking to prevent and reverse, if possible, neurodegeneration and address prodromal conditions, Lucid has preclinical assets under development.